Multiple Myeloma Measurable Residual Disease (MRD), Flow Cytometry, Bone Marrow

Use

Detecting low-level measurable residual disease (MRD) in patients with multiple myeloma post-therapy is a significant prognostic marker. The presence of MRD indicates remaining cancerous plasma cells, which can predict patient outcomes. This test employs high-sensitivity flow cytometry, following EuroFlow guidelines, to assess MRD levels with a sensitivity of 10(-5) or better. It is essential for monitoring remission and guiding treatment decisions post-chemotherapy or autologous stem cell transplantation in multiple myeloma patients.